Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort.

Introduction: Atopic dermatitis (AD) is a common chronic inflammatory disease during adolescence, with severe forms having a particularly high impact on patients' quality of life. Several therapeutic options are currently approved for the treatment of AD in individuals over 12 years of age. This study evaluated the efficacy and safety of tralokinumab in adolescent patients, with a particular focus on identifying which patient profiles may derive the greatest benefit from this therapy.

Methods: A retrospective multicenter study was conducted across nine Spanish hospitals, including patients from 12 to 17 years old with moderate-to-severe AD treated with tralokinumab.

Results: A total of 27 patients were included, with a mean age of 14.8 years. Nine had previously received treatment with dupilumab, five due to primary or secondary failure, and four due to adverse events. One patient had been treated with upadacitinib, which was discontinued because of primary failure and acne. A statistically significant reduction was achieved in Eczema Area and Severity Index (EASI), pruritus visual analog scale (VAS), and Investigator's Global Assessment (IGA) scores. Palmoplantar involvement was observed in 44.4% of patients; after 24 weeks of treatment, 83.3% of those with palmoplantar involvement experienced complete resolution. Additionally, 37.0% of patients were overweight or obese, with no statistically significant differences in treatment efficacy.

Conclusion: Tralokinumab demonstrated efficacy and safety in the treatment of moderate-to-severe AD in patients aged 12-17 years. Notably, the treatment was effective in adolescent patients with palmoplantar involvement and/or obesity.